These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22891286)
21. Therapeutic efficacy against Baldwin SL; Reese VA; Larsen SE; Pecor T; Brown BP; Granger B; Podell BK; Fox CB; Reed SG; Coler RN Front Microbiol; 2022; 13():935444. PubMed ID: 36090093 [No Abstract] [Full Text] [Related]
22. Therapeutic Vaccines for Tuberculosis: An Overview. Bouzeyen R; Javid B Front Immunol; 2022; 13():878471. PubMed ID: 35812462 [TBL] [Abstract][Full Text] [Related]
23. Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Lee JM; Park J; Reed SG; Coler RN; Hong JJ; Kim LH; Lee W; Kwon KW; Shin SJ Virulence; 2022 Dec; 13(1):808-832. PubMed ID: 35499090 [No Abstract] [Full Text] [Related]
24. Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis. Carpenter SM; Lu LL Front Immunol; 2022; 13():830482. PubMed ID: 35371092 [TBL] [Abstract][Full Text] [Related]
25. It Takes a Village: The Multifaceted Immune Response to Larsen SE; Williams BD; Rais M; Coler RN; Baldwin SL Front Immunol; 2022; 13():840225. PubMed ID: 35359957 [TBL] [Abstract][Full Text] [Related]
26. An Update on Tuberculosis Vaccines. Gopalaswamy R; Subbian S Methods Mol Biol; 2022; 2410():387-409. PubMed ID: 34914059 [TBL] [Abstract][Full Text] [Related]
27. Enhancement of CD4 Costa DL; Amaral EP; Namasivayam S; Mittereder LR; Andrade BB; Sher A Front Cell Infect Microbiol; 2021; 11():672527. PubMed ID: 34235093 [TBL] [Abstract][Full Text] [Related]
28. Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Larsen SE; Reese VA; Pecor T; Berube BJ; Cooper SK; Brewer G; Ordway D; Henao-Tamayo M; Podell BK; Baldwin SL; Coler RN Sci Rep; 2021 Apr; 11(1):9040. PubMed ID: 33907221 [TBL] [Abstract][Full Text] [Related]
38. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Kwon KW; Lee A; Larsen SE; Baldwin SL; Coler RN; Reed SG; Cho SN; Ha SJ; Shin SJ Sci Rep; 2019 Oct; 9(1):15560. PubMed ID: 31664157 [TBL] [Abstract][Full Text] [Related]
39. Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation. Afkhami S; Lai R; D'agostino MR; Vaseghi-Shanjani M; Zganiacz A; Yao Y; Jeyanathan M; Xing Z J Infect Dis; 2019 Sep; 220(8):1355-1366. PubMed ID: 31198944 [TBL] [Abstract][Full Text] [Related]
40. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. Baldwin SL; Larsen SE; Ordway D; Cassell G; Coler RN PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007083. PubMed ID: 30763316 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]